Best of the Week
Most Popular
1. Ray Dalio: This Debt Cycle Will End Soon - John_Mauldin
2.Stock Market Dow Plunge Following Fake US - China Trade War Truce - Nadeem_Walayat
3.UK House Prices 2019 No Deal BrExit 30% Crash Warning! - Nadeem_Walayat
4.What the Oil Short-sellers and OPEC Don’t Know about Peak Shale - Andrew_Butter
5.Stock Market Crashed While the Yield Curve Inverted - Troy_Bombardia
6.More Late-cycle Signs for the Stock Market and What’s Next - Troy_Bombardia
7.US Economy Will Deteriorate Over Next Half Year. What this Means for Stocks - Troy_Bombardia
8.TICK TOCK, Counting Down to the Next Recession - James_Quinn
9.How Theresa May Put Britain on the Path Towards BrExit Civil War - Nadeem_Walayat
10.This Is the End of Trump’s Economic Sugar High - Patrick_Watson
Last 7 days
Gold Stocks Triple Breakout - 15th Dec 18
The stock market fails to rally each day. What’s next for stocks - 14th Dec 18
How Low Could the S&P 500 Go? - 14th Dec 18
An Industrial to Stock Trade: Is Boeing a BUY Here? - 14th Dec 18
Will the Arrest of Huawei Executive Derail Trade War Truce? - 14th Dec 18
Trump vs the Fed: Who Wins? - 13th Dec 18
Expect Gold & Silver to Pullback Before the Next Move Higher - 13th Dec 18
Dollar Index Trends, USDJPY Setting Up - 13th Dec 18
While The Stocks Bulls Fiddle With The 'Fundamentals,' Rome Burns - 13th Dec 18
The Historic Role of Silver - 13th Dec 18
Natural Gas Price Setup for a Big Move Lower - 13th Dec 18
How to Get 20% Off Morrisons Weekly Supermarket Shopping - 13th Dec 18
Gold Price Analysis: Closer To A Significant Monetary Event - 13th Dec 18
Where is the Stock Market Santa Claus Rally? - 12th Dec 18
Politics and Economics in Times of Crisis - 12th Dec 18
Owning Precious Metals in an IRA - 12th Dec 18
Ways to Improve the Value of Your Home - 12th Dec 18
Theresa May No Confidence Vote, Next Tory Leader Betting Market Analysis and Forecasts - 12th Dec 18
Gold & Global Financial Crisis Redux - 12th Dec 18
Wow Your Neighbours With the Best Christmas Projector Lights for Holidays 2018! - 12th Dec 18
Stock Market Topping Formation as Risks Rise Around the World - 11th Dec 18
The Amazing Story of Gold to Gold Stocks Ratios - 11th Dec 18
Stock Market Medium term Bullish, But Long Term Risk:Reward is Bearish - 11th Dec 18
Is a Deleveraging Event about to Unfold in the Stock Market? - 11th Dec 18
Making Money through Property Investment - 11th Dec 18
Brexit: What Will it Mean for Exchange Rates? - 11th Dec 18
United States Facing Climate Change Severe Water Stress - 10th Dec 18
Waiting for Gold Price to Erupt - 10th Dec 18
Stock Market Key Support Being Re-Tested - 10th Dec 18
May BrExit Deal Tory MP Votes Forecast, Betting Market Analysis - 10th Dec 18
Listen to What Gold is Telling You - 10th Dec 18
The Stock Market’s Long Term Outlook is Changing - 10th Dec 18
Palladium Shortages Expose Broken Futures Markets for Precious Metals - 9th Dec 18
Is an Inverted Yield Curve Bullish for Gold? - 9th Dec 18
Rising US Home Prices and Falling Sales - 8th Dec 18
Choosing Who the Autonomous Car Should Kill - 8th Dec 18
Stocks Selloff Boosting Gold - 8th Dec 18

Market Oracle FREE Newsletter

How You Could Make £2,850 Per Month

How to Ride the Biotech Boom

Companies / BioTech Jul 10, 2013 - 04:24 PM GMT

By: Investment_U

Companies

Marc Lichtenfeld writes: hope you had a great Fourth of July. I had a blast hanging out with family and friends. However, we had a long drive home so we missed the fireworks.

That’s OK, though. I’ve seen plenty of fireworks in the past two weeks in the biotech sector.

Since June 24, the Amex Biotech Index (NYSE: BTK) is up over 11%. That’s a solid year for most indexes. Year to date, the group is up over 34%.


Typically, biotech stocks, particularly those that deal with cancer, run up in the spring, ahead of the annual meeting of the American Society of Clinical Oncology (ASCO). At this meeting, nearly every major (and minor) player in the fight against cancer presents data from various clinical and preclinical trials.

After the ASCO meeting, which takes place the first week of June, biotech stocks usually take a breather, sometimes for the rest of the year until they start moving in anticipation of the J.P. Morgan Healthcare Conference – the first big one of the year – in early January.

Acquisition Fever Fuels Run-up
This year, biotech hit a high in mid-May and then backed off. But in late June the sector ignited. Fueling the fire was the proposed acquisition of Onyx Pharmaceuticals (Nasdaq: ONXX) by Amgen (Nasdaq: AMGN) for a 38% premium.

Onyx’s management rejected the proposal and put itself up for sale. The stock opened 53% higher and has climbed a few points since.

Other cancer stocks have also soared. ImmunoGen (Nasdaq: IMGN) is up 20% in the past few weeks. And Celldex Therapeutics (Nasdaq: CLDX), which has drugs in development for brain cancer and breast cancer, has spiked 63% in just two weeks.

Fortunately, these stocks are in my Healthcare Profits Alert service, so my subscribers have been enjoying the ride higher. But there have been plenty of other biotech stocks that are not in the portfolio that have been moving up as well: Alnylam (Nasdaq: ALNY), and Immunomedics (Nasdaq: IMMU) to name just a few.

Can the run-up continue? I believe it can.

Right now there is a lot of excitement over a possible acquisition of Onyx. If the company does in fact get bought at a decent premium, that’s going to make takeover speculation go into overdrive.

Plus, big pharmaceutical companies desperately need new drugs. And biotech can provide them. Smaller companies like Celldex Therapeutics can be bought at a much lower price than a larger company like Onyx. There are many small-cap biotechs with promising drugs that would not be an expensive purchase for a large pharma company like Merck (NYSE: MRK) or Bristol-Myers Squibb (NYSE: BMY).

Additionally, the technicals look strong:

The index recently broke out of a flag pattern. A flag is a short-term move that goes against the prevailing trend. You can see that the biotech index has been moving up since November, but in May and June the index took a break from its ascent. Now it has broken out above that flag pattern.

Flags are fairly reliable technical patterns. This one suggests that the index can still go meaningfully higher. I wouldn’t be surprised to see it hit 2,300 before the move is over.

How to Play It
If you agree, there are several ways to play this move. You can buy a biotech ETF like iShares Nasdaq Biotechnology (Nasdaq: IBB); you can find some biotech stocks with promising drugs that have shown efficacy and (very important) a strong safety profile in clinical trials; or you can rely on someone to help guide you, like the readers of my Healthcare Profits Alert do.

Whichever way you go, consider putting some of your speculative money to work in this sector, as there should be more spectacular gains on the way.

Editor’s Note: We need to tip our collective hats to Marc. As he mentions above, he is treating his followers to phenomenal profits. A perfect example comes from an alert he mailed his Healthcare Profits Alert subscribers yesterday. In it, Marc details the action to take on four profitable positions. One has tripled in price. Another is up by 229%. The third play is up 67%. And the fourth is up by 7%… in less than a month. Clearly, market volatility won’t shake Marc’s winning system. And that deserves a tip of our hat. To be one of the first to hear about his next winning recommendation, follow this link.

Source: http://www.investmentu.com/2013/July/ride-the-biotech-boom.html

http://www.investmentu.com

Copyright © 1999 - 2013 by The Oxford Club, L.L.C All Rights Reserved. Protected by copyright laws of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), of content from this website, in whole or in part, is strictly prohibited without the express written permission of Investment U, Attn: Member Services , 105 West Monument Street, Baltimore, MD 21201 Email: CustomerService@InvestmentU.com

Disclaimer: Investment U Disclaimer: Nothing published by Investment U should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Investment U should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Investment U Archive

© 2005-2018 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

6 Critical Money Making Rules